{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T12:42:52Z","timestamp":1722948172484},"reference-count":9,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.3892\/ol.2015.3463","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T07:06:11Z","timestamp":1436339171000},"page":"1277-1280","source":"Crossref","is-referenced-by-count":4,"title":["Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report"],"prefix":"10.3892","volume":"10","author":[{"given":"YI-CHEN","family":"LIANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GANG","family":"WU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JING","family":"CHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DAN-DAN","family":"YU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HONG-GE","family":"WU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,7,8]]},"reference":[{"key":"key20180108100107_b1-ol-0-0-3463","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180108100107_b2-ol-0-0-3463","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1634\/theoncologist.11-4-358","article-title":"Clinical implications of EGFR expression in the development and progression of solid tumors: Focus on non-small cell lung cancer","volume":"11","author":"Ettinger","year":"2006","journal-title":"Oncologist"},{"key":"key20180108100107_b3-ol-0-0-3463","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/JTO.0000000000000156","article-title":"Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations","volume":"9","author":"Haaland","year":"2014","journal-title":"J Thorac Oncol"},{"key":"key20180108100107_b4-ol-0-0-3463","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180108100107_b5-ol-0-0-3463","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/archderm.144.11.1525","article-title":"Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition","volume":"144","author":"Hartmann","year":"2008","journal-title":"Arch Dermatol"},{"key":"key20180108100107_b6-ol-0-0-3463","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3181ca12e0","article-title":"Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: The Okayama Lung Cancer Study Group experience","volume":"5","author":"Hotta","year":"2010","journal-title":"J Thorac Oncol"},{"key":"key20180108100107_b7-ol-0-0-3463","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1756-0500-2-157","article-title":"Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02","volume":"2","author":"Nakagawa","year":"2009","journal-title":"BMC Res Notes"},{"key":"key20180108100107_b8-ol-0-0-3463","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cllc.2014.04.006","article-title":"Management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: A comparison analysis","volume":"15","author":"Passaro","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"key20180108100107_b9-ol-0-0-3463","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/0019-5154.131398","article-title":"Dermatological side effects of epidermal growth factor receptor inhibitors: \u2018PRIDE\u2019 complex","volume":"59","author":"Madke","year":"2014","journal-title":"Indian J Dermatol"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2015.3463\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T11:57:25Z","timestamp":1515412645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2015.3463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,8]]},"references-count":9,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,7,8]]},"published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.3892\/ol.2015.3463"],"URL":"https:\/\/doi.org\/10.3892\/ol.2015.3463","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,8]]}}}